RA
Rosalind Advisors Portfolio holdings
AUM
$207M
This Quarter Return
+27.19%
1 Year Return
+62.29%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$186M
AUM Growth
+$186M
(+23%)
Cap. Flow
-$34.3M
Cap. Flow
% of AUM
-18.47%
Top 10 Holdings %
Top 10 Hldgs %
69.28%
Holding
47
New
9
Increased
5
Reduced
10
Closed
10
Top Buys
| 1 |
CMRX
Chimerix, Inc.
CMRX
|
$10.6M |
| 2 |
UroGen Pharma
URGN
|
$9.27M |
| 3 |
Savara
SVRA
|
$8.15M |
| 4 |
Fennec Pharmaceuticals
FENC
|
$7.96M |
| 5 |
Verastem
VSTM
|
$4.65M |
Top Sells
| 1 |
OPTN
OptiNose
OPTN
|
$49.5M |
| 2 |
CorMedix
CRMD
|
$11.9M |
| 3 |
Cellectar Biosciences
CLRB
|
$7.86M |
| 4 |
VRNA
Verona Pharma
VRNA
|
$5.81M |
| 5 |
Outlook Therapeutics
OTLK
|
$2.4M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Delcath Systems
DCTH
$385M
| $31.9M | 16.32% | 2,650,389 | – | – |
|
2
Myomo
MYO
$39.7M
| $19.3M | 9.88% | 2,998,945 -22,446 | -0.7% | -$145K |
|
3
MediWound
MDWD
$182M
| $11.2M | 5.72% | 628,050 | – | – |
|
|
CMRX
4
DELISTED
Chimerix, Inc.
CMRX
| $10.6M | 5.43% | +3,050,000 | New | +$10.6M |
|
5
Xeris Biopharma Holdings
XERS
$1.26B
| $10.5M | 5.38% | 3,104,995 | – | – |
|
6
Abeona Therapeutics
ABEO
$350M
| $10.1M | 5.14% | 1,805,390 -26,610 | -1% | -$148K |
|
7
Ocular Therapeutix
OCUL
$2.12B
| $9.64M | 4.93% | 1,128,700 +243,700 | +28% | +$2.08M |
|
|
8
UroGen Pharma
URGN
$900M
| $9.27M | 4.74% | +870,000 | New | +$9.27M |
|
|
9
Savara
SVRA
$567M
| $8.15M | 4.17% | +2,654,944 | New | +$8.15M |
|
|
10
Fennec Pharmaceuticals
FENC
$247M
| $7.96M | 4.07% | +1,259,876 | New | +$7.96M |
|
|
CYBN
11
Cybin
CYBN
$176M
| $7.15M | 3.66% | 810,918 -264,187 | -25% | -$2.33M |
|
|
VRNA
12
Verona Pharma
VRNA
$9.16B
| $6.97M | 3.56% | 150,000 -125,000 | -45% | -$5.81M |
|
13
InspireMD
NSPR
$102M
| $6.56M | 3.36% | 2,495,783 -18,263 | -0.7% | -$48K |
|
|
OPTN
14
DELISTED
OptiNose
OPTN
| $5.86M | 3% | 876,996 -7,410,507 | -89% | -$49.5M |
|
|
PROF
15
Profound Medical
PROF
$134M
| $5.2M | 2.66% | 692,185 +206,212 | +42% | +$1.55M |
|
|
16
Verastem
VSTM
$569M
| $4.65M | 2.38% | +900,000 | New | +$4.65M |
|
17
Trevi Therapeutics
TRVI
$883M
| $4.38M | 2.24% | 1,062,500 +312,500 | +42% | +$1.29M |
|
18
Replimune Group
REPL
$422M
| $3.15M | 1.61% | +260,000 | New | +$3.15M |
|
19
PolyPid
PYPD
$53.3M
| $3.09M | 1.58% | 1,018,021 +338,853 | +50% | +$1.03M |
|
|
CMPS
20
Compass Pathways
CMPS
$424M
| $2.67M | 1.37% | 707,625 -73,798 | -9% | -$279K |
|
21
KalVista Pharmaceuticals
KALV
$678M
| $2.57M | 1.32% | 303,864 | – | – |
|
|
ACOG
22
Alpha Cognition Inc. Common Stock
ACOG
$134M
| $1.49M | 0.76% | +252,753 | New | +$1.49M |
|
23
Cassava Sciences
SAVA
$110M
| $985K | 0.5% | +417,400 | New | +$985K |
|
24
Biofrontera
BFRI
$9.45M
| $885K | 0.45% | 811,918 +316,428 | +64% | +$345K |
|
25
Kiora Pharmaceuticals
KPRX
$9.55M
| $827K | 0.42% | 250,555 -5,000 | -2% | -$16.5K |
|